More Neuren Pharmaceuticals Limited news
Neuren Pharmaceuticals LimitedASX: NEU

S&P DJI Announces March 2021 Quarterly Rebalance

Mar 12, 2021 at 6:23 AM EST · Issued by Neuren Pharmaceuticals Limited

Filed with ASX · Mar 12, 2021 at 6:23 AM EST · 9 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-march-2021-quarterly-rebalance-72

Neuren Pharmaceuticals Limited on 6ix

Earlier from Neuren Pharmaceuticals

  • Neuren successfully completes manufacturing for Phase 2Mar 9, 2021
  • Neuren approaching transforming milestones in 2021Feb 23, 2021
  • Preliminary Final Report and 2020 full year accountsFeb 23, 2021
  • Neuren adds Prader-Willi syndrome to NNZ-2591 pipelineFeb 15, 2021
  • Successful Phase 1 trial for Neurens NNZ-2591Feb 14, 2021

Later from Neuren Pharmaceuticals

  • Quarterly report and cash flow statement for Q1 2021Apr 22, 2021
  • New patent issued to 2032 for Neurens trofinetide in CanadaApr 28, 2021
  • Positive FDA meetings enable INDs for three Phase 2 trialsMay 31, 2021
  • Q2 2021 quarterly activity and cash flow reportJul 30, 2021
  • Phase 3 enrolment successfully completed, results in Q4 2021Aug 4, 2021
All Neuren Pharmaceuticals news releases↗

Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.

Follow Neuren Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer